Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

4 results about "Binding protein" patented technology

A binding protein is any protein that acts as an agent to bind two or more molecules together. Examples include: DNA-binding protein Single-strand binding protein Telomere-binding protein RNA-binding protein Poly-binding protein Nuclear cap-binding protein complex CREB-binding protein Calcium-binding protein Calcium-binding protein 1 S100 calcium-binding protein A1 TATA-binding protein Actin-binding protein Penicillin binding proteins Retinol binding protein Retinol binding protein 4 EP300 Binding immunoglobulin protein Odorant binding protein Lipopolysaccharide-binding protein C4b-binding protein Rap GTP-binding protein Calmodulin-binding proteins Iron-binding proteins Thyroxine-binding proteins Folate-binding protein Sterol regulatory element-binding protein GTP-binding protein Retinaldehyde-binding protein 1 Ccaat-enhancer-binding proteins Androgen-binding protein Maltose-binding protein Phosphatidylethanolamine binding protein 1 Syntaxin binding protein 3 Insulin-like growth factor-binding protein Methyl-CpG-binding domain protein 2 Growth hormone-binding protein Vitamin D-binding protein Syntaxin binding protein 2 Oxysterol-binding protein E3 binding protein

Methods for the diagnosis, prognosis and treatment of metabolic syndrome

InactiveUS20060211020A1Sugar derivativesPeptide/protein ingredientsPhosphatidate cytidylyltransferaseGlycerol kinase
The present invention provides methods for detecting susceptibility to metabolic syndrome. In particular, the presence of differences in at least one of the following genes; microsomal triglyceride transfer protein (MTP), fatty acid binding protein 2 (FABP2), annexin A5 (ANXA5), pyruvate dehydrogenase (lipoamide) alpha 2 (PDHA2), CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 (CDS 1), and glycerol kinase 2 (GK2) serves as a prognostic and diagnostic indicator of metabolic syndrome. Furthermore, metabolic syndrome can be treated by regulating the levels of MTP, FABP2, ANXA5, PDHA2, CDS1, and GK2.
Owner:TRUSTEES OF BOSTON UNIV

Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob

InactiveUS7297542B2Efficient transductionRaise transfer toBiocideAntibody mimetics/scaffoldsHeterologousEpitope
The present invention provides means to modify the tropism of recombinant adenoviral vectors using genetic methods to alter the adenoviral fiber cell-binding protein. The present invention generates an adenovirus with modified fiber gene such that novel tropism is achieved. This recombinant adenovirus has a fiber gene modified in the HI loop domain.
Owner:UAB RES FOUND

Novel photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes

PendingUS20220137064A1Avoid artifactsOrganic chemistryMicrobiological testing/measurementMass spectrometry imagingPathology diagnosis
The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).
Owner:AMBERGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products